Professional services offered by BJC Capital Advisors represents the aggregation and integration of functions critical to the success of companies in the biopharmaceutical industry, especially earlier-stage companies. The distinguished talent assembled by the firm across these core capabilities provides seamless interaction, aligns longer term interests and deepens client relationships. We invite you to learn more about these offerings.
Partnering and M&A Advisory Services
Strategic transaction advisory services are a core expertise of the firm where we have represented companies in both sell-side and buy-side engagements. When involved in sell-side engagements, we work as integral partners with company management to optimally position corporate assets to attain maximum valuations. Often this effort requires significant consideration and preparation in advance of initiating a robust outreach program and includes an assessment of the inherent commercial potential of a company’s products and development candidates together with intensive partner scrutiny to identify the partner and deal structure likely to align best with our client and its objectives. We then manage and coordinate all elements of the sale process, from initial outreach to transaction completion. Buyside transactions entail initial alignment on corporate development strategy prior to initiating asset screens to determine the most attractive partnering or acquisition opportunities. Blinded outreach is then conducted to determine a target’s receptiveness to a potential transaction and project a client’s interest in the best possible light. We take an active role in all subsequent due diligence inquiries, valuation and deal structuring and negotiations. For publicly traded client companies we can also provide the board of directors with a fairness opinion in support of a transaction.
Private Equity Placements
Prior to engaging in a private equity placement for a company, we spend considerable time conducting a impartial review of its technology and development programs as well as its executive management team to gauge potential investor interest and validate its ability to achieve key value inflection points with the targeted funding. During this period, we tap into the considerable industry and capital markets expertise resident within the firm, augmented by our extensive network of external advisors and key opinion leaders. Significant time is then spend with management to build consensus around company positioning to ensure alignment between the strategic intent articulated by company executives and investment community appetite. We work with management to develop and refine key investor themes as well as construct an impactful corporate presentation and assist in preparation and delivery. We then access an extensive array of established contacts at both strategic and financial institutional sponsors, focusing on those entities with expressed interest in a particular company’s profile. Our role includes assisting the company in the construction of virtual data room, deal structuring and negotiation, support in legal documentation and closing of the transaction in an expeditious timeframe.
Interim or Fractional CMO/CBO executive network
Many biopharmaceutical companies, especially the emerging or early-stage companies, have a need to access seasoned chief medical officer (CMO) and chief business officer (CBO) executives. Access to this talent in the initial definition of a development program offers numerous benefits, including alignment with the expectations of a larger pharmaceutical partner and the avoidance of costly and time-consuming delays in program execution.
Many of these companies don’t have an immediate need to hire a dedicated, full-time CMO or CBO. To that end, we have assembled an aggregate of very senior and capable industry executives that can be accessed by biopharma companies, especially emerging and early-stage companies, in a way that best works for them, whether it’s a day a month, a day each week or on a dedicated basis but for some specifically defined period of time. This model is intended to allow a company to scale its use of the function (and the associated expense) as best fits its development. The company isn’t burdened by its commitment to a highly salaried employee, doesn’t have to pay recruiter fees or deal with large stock-option allocations. Moreover, the talent, with expertise across a range of therapeutic areas, drug development stages and therapeutic technologies, is at an experience level that most companies would likely be unable to attract regardless.
IPO Advisory Services
The drafting of the business section of an SEC Form S-1 or F-1 registration statement is a critical step in initiating the IPO process and its thoughtful preparation of vital importance in building public market interest and enthusiasm. A well-crafted document ahead of the organizational meeting can also significantly shorten what is often the most time-consuming portion of the registration effort. Its completion requires the integration of disparate talents, including an intimate appreciation of life sciences, capital markets savvy and perspective on SEC scrutiny. We have drafted numerous completed IPOs for companies targeting a range of disease indications employing diverse technologies with many more filed on behalf of our clients. We are highly experienced in this process and have a team of specialists eager to assist.
Securities related transactions executed through BJC Capital Advisors LLC, a registered broker/dealer. Member FINRA/SIPC